Connect Conference & Show Floor Educational Sessions

View, browse and sort the list of Connect Conference sessions and show floor programming by pass type, track, and format. Please note, all Connect Conference delegates have access to InformEx Connect and CPhI Connect programming. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

To learn more about the Connect Conference program, click here.

All SessionsSpeakersMy Schedule
View Sessions As:
  • David ConlonSenior Principal ScientistBristol-Myers Squibb

    Dr. David A. Conlon joined the Chemical & Synthetic Development Department at Bristol-Myers Squibb in 2006 where he is currently a Senior Principal Scientist. In this role he is responsible for multiple project teams engaged in the discovery, optimization and implementation of synthetic routes used for the preparation of novel drug candidates in multiple therapeutic areas including virology, oncology, CNS and immunology.

    Prior to joining Bristol-Myers Squibb, he held positions of increasing responsibility in the Process Research Department at Merck & Co. Inc. in Rahway, NJ. Dr. Conlon was a key member of the Merck technical teams that transferred the asthma drug Singulair® and the antifungal Cancidas® from the research laboratories to the manufacturing division.
    Dr. Conlon earned his B.S. degree in chemistry from Union College in Schenectady, NY and his Ph.D. from the University of Rochester where he studied with Prof. Joseph P. Dinnocenzo. Prior to entering graduate school he was employed by General Electric at the Corporate Research and Development Center in Niskayuna, NY.

    Dr. Conlon has experience in all aspects of the process design, optimization and development of synthetic routes to pharmaceutical intermediates and active pharmaceutical ingredients. He is the author or co-author on over 60 publications, 4 book chapters and 8 U.S. patents. He is a member of the Editorial Advisory Board (EAB) for the American Chemical Society (ACS) Journal Organic Process Research & Development (OPR&D) and a Councilor on the Executive Committee of the ACS Division of Organic Chemistry (DOC).